Prolactin (PRL) is a polypeptide hormone produced by the anterior pituitary gland and other sites that acts both systemically and locally to cause lactation and other biological effects by interacting with the PRL receptor, a Janus kinase (JAK)2-coupled cytokine receptor family member, and activating downstream signal pathways. Recent evidence suggests PRL is a player in the pathogenesis and progression of breast cancer. Epidermal growth factor (EGF) also has effects on breast tissue, working through its receptors, epidermal growth factor receptor (EGFR) and ErbB-2 (c-neu, HER2), both intrinsic tyrosine kinase growth factor receptors. EGFR promotes pubertal breast ductal morphogenesis in mice, and both EGFR and ErbB-2 are relevant in pathogenesis and behavior of breast and other human cancers. Previous studies showed that PRL and EGF synergize to enhance motility in the human breast cancer cell line, T47D. In this study, we explored crosstalk between the PRL and EGF signaling pathways in T47D cells, with an ultimate aim of understanding how these two important factors might work together in vivo to affect breast cancer behavior. Both PRL and EGF caused robust signaling in T47D cells; PRL acutely activated JAK2, signal transducer and activator of transcription-5 (STAT5), and extracellular signal-regulated kinase-1 and -2 (ERK1 and ERK2), whereas EGF caused EGFR activation and consequent src homology collagen (SHC) activation and ERK activation. Notably, PRL also caused phosphorylation of the EGFR and ErbB-2 at sites detected by PTP101, an antibody that recognizes threonine phosphorylation at consensus motifs for ERK-induced phosphorylation. PRL-induced PTP101-reactive phosphorylation was prevented by pretreatment with PD98059, an ERK pathway inhibitor. Furthermore, PRL synergized with EGF in activating SHC and ERK and transactivating a luciferase reporter driven by c-fos gene enhancer elements, suggesting that PRL allowed markedly enhanced EGF signaling. This was accompanied by substantial inhibition of EGF-induced EGFR downregulation when PRL and EGF cotreatment was compared to EGF treatment alone. This effect of PRL was abrogated by ERK pathway inhibitor pretreatment. Our data suggest that PRL synergistically augments EGF signaling in T47D breast cancer cells at least in part by lessening EGF-induced EGFR downregulation and that this effect requires PRL-induced ERK activity and threonine phosphorylation of EGFR.
Introduction
Prolactin (PRL) is a polypeptide hormone produced mainly by the anterior pituitary gland that acts systemically as a classical endocrine factor. It is also produced locally by multiple extrapituitary sites, including the mammary epithelium, placenta, uterus, bone, brain and immune system, and can act in an autocrine/ paracrine manner (Ben-Jonathan et al., 1996; Freeman et al., 2000) . PRL stimulates normal mammary growth, development and lactation, but also affects other reproductive aspects,such as osmoregulation, stress and behavior (Horseman, 1999; Rui, 2000; Hovey et al., 2001; Goffin et al., 2002; Grimm et al., 2002) . Although controversial, the contribution of PRL to the pathogenesis and progression of human breast cancer is increasingly appreciated (Hankinson et al., 1999; Vonderhaar, 1999; Llovera et al., 2000b; Ben-Jonathan et al., 2002; Clevenger et al., 2003) . PRL signals via the PRL receptor (PRLR), a cytokine receptor family member, which possesses no intrinsic tyrosine kinase activity and couples to the nonreceptor tyrosine kinase, Janus kinase (JAK)2 (Bazan, 1990; Argetsinger et al., 1993; Campbell et al., 1994; Rui et al., 1994; Bole-Feysot et al., 1998) . Among other pathways, PRL activates the extracellular signal-regulated kinase (ERK) and STAT signaling pathways, with STAT5a being the principal STAT isoform involved in its mammary effects (Campbell et al., 1994; Rui et al., 1994; Liu et al., 1997; Clevenger and Kline, 2001) . PRL induces ERK activity in several breast cancer cell lines, which may be important in PRL-induced biological effects in these cells (Das and Vonderhaar, 1996a, b; Llovera et al., 2000a; Schroeder et al., 2002; Acosta et al., 2003) . In some cases, PRL synergizes with other growth factors in activating ERK (Clevenger et al., 2003) .
Epidermal growth factor (EGF) and its family members (e.g., transforming growth factor-a) affect cell growth, differentiation, motility, adhesion and tumorigenesis by interaction with the EGF receptor (EGFR), a transmembrane tyrosine kinase growth factor receptor (Boonstra et al., 1995; Mendelsohn and Baselga, 2000; Holbro et al., 2003; Mendelsohn and Baselga, 2003; Shilo, 2003) . EGFR, also known as ErbB-1, is the prototype of the ErbB family, which also includes ErbB-2 (c-neu, HER2), ErbB-3 and ErbB-4 (Lin et al., 1984; Bargmann et al., 1986; Kraus et al., 1989; Plowman et al., 1993) . ErbB-2 has no ligand, but its basal activity is increased by EGF-like ligands. By heterodimerizing with ErbB members, ErbB-2 augments EGF/EGF-like ligand signaling (Karunagaran et al., 1996; Graus-Porta et al., 1997) . EGFR promotes pubertal breast ductal morphogenesis in mice, and both EGFR and ErbB-2 are relevant in pathogenesis and behavior of breast and other human cancers (Berger et al., 1988; Xie et al., 1997; Biscardi et al., 2000; Mendelsohn and Baselga, 2000; Stern, 2000; Mendelsohn and Baselga, 2003) . Increased expression and signaling of EGFR and/or ErbB-2 is associated with more aggressive clinical behavior and correlates with a poor prognosis (Alroy and Yarden, 1997) .
Although much is known about signaling by cytokines and growth factors, relatively little is known about how their signaling pathways may interact to exert biological effects. Recent studies suggest that PRL, growth hormone (GH) and other cytokines may use multiple mechanisms to crosstalk with EGFR and/or ErbB-2 (Johnson et al., 1996; Fenton and Sheffield, 1997; Wiepz et al., 1997; Yamauchi et al., 1997 Yamauchi et al., , 1998 Yamauchi et al., , 2000 Qiu et al., 1998; Quijano and Sheffield, 1998; Kim et al., 1999; Maus et al., 1999; Badache and Hynes, 2001; Huang et al., 2003) . For example, GH causes EGFR tyrosine phosphorylation without the activation of EGFR kinase activity (Yamauchi et al., 1997; Kim et al., 1999) . In that case, GH-induced tyrosinephosphorylated EGFR binds Grb2 and enhances GH-induced ERK activation. GH also causes ERKmediated threonine phosphorylation of EGFR and ErbB-2 (Kim et al., 1999; Huang et al., 2003) . The effect of GH-induced EGFR threonine phosphorylation in murine preadipocytes is to dampen subsequent EGFinduced EGFR downregulation, augmenting signaling of the activated receptor (Huang et al., 2003) .
Effects of PRL on EGF signaling have been studied by Sheffield et al. in normal mammary epithelial cells. In these studies, PRL induced threonine phosphorylation of the EGFR (Fenton and Sheffield, 1993; Johnson et al., 1996; Quijano and Sheffield, 1998) . Whereas the sites of phosphorylation were not mapped, pharmacologic data suggested that it might be dependent on protein kinase C (PKC) activation. In these cells, PRLinduced EGFR phosphorylation correlated with decreased subsequent EGF-induced EGFR kinase activity and signaling. In contrast to this apparent inhibitory effect of PRL on EGF signaling in normal mammary epithelial cells, costimulation of several human breast cancer cell lines, including T47D, MCF-7 and MDA-231, revealed that PRL and EGF synergize to enhance cell motility (Maus et al., 1999) , suggesting potentially important context-specific elements of crosstalk between these two factors.
In this study, we examine mechanisms and consequences of PRL-EGF crosstalk in T47D breast cancer cells. In particular, we focus on the effects of PRL on the phosphorylation status of EGFR and ErbB-2, EGFinduced signaling and modulation of EGFR downregulation and trafficking. We find that PRL causes ERK-dependent threonine phosphorylation of both EGFR and ErbB-2 and that this correlates with retardation of EGF-induced EGFR degradation and enhanced EGF signaling. These novel findings suggest important crosstalk mechanisms that may be relevant for breast cancer behavior and susceptible to therapeutic intervention.
Results

PRL promotes ERK-dependent threonine phosphorylation of EGFR and ErbB2
Here, we used the T47D human breast cancer cell line, which is a model system for studies of PRL and EGF action in breast cancer biology (Das and Vonderhaar, 1996a, b; Haraguchi et al., 1997; Gibson et al., 1999; Maus et al., 1999; Badache and Hynes, 2001; Lichtner et al., 2001; Chen et al., 2002; Chughtai et al., 2002; Kassenbrock et al., 2002; Acosta et al., 2003) . We first tested responsiveness to each stimulus in these cells. In Figure 1a , serum-starved T47D cells were exposed to vehicle or EGF (1 nM) for 15 min before detergent extraction. Extracted proteins were either resolved directly by SDS-PAGE and immunoblotted sequentially with an antibody that detects active ERK (antipERK) and total ERK (lower panels) or immunoprecipitated with anti-EGFR and blotted sequentially with anti-phosphotyrosine antibody (anti-pTyr) and anti-EGFR (upper panels). As expected, EGF acutely promoted EGFR tyrosine phosphorylation and ERK activation. PRL responsiveness was tested in the experiments in Figure 1b and c. In these experiments, serum-starved cells were treated with 500 ng/ml PRL for 0-60 min ( Figure 1b) or with 0-500 ng/ml PRL for 15 min (Figure 1c ) and extracted proteins were resolved and sequentially immunoblotted with anti-pSTAT5, anti-STAT5, anti-pERK and anti-ERK antibodies, as indicated. Both STAT5 and ERK activation were detectable after 5 min of PRL (500 ng/ml) exposure and achieved maximal stimulation after 15 min, although STAT5 activity was more sustained. Detectable activation of both signals was observed with 20 ng/ ml PRL after 15 min and increased with higher PRL concentrations. These data indicate the PRL and EGF responsiveness of T47D cells make them an appealing system to study potential crosstalk between the PRL and EGF signaling pathways.
We previously reported that in mouse preadipocytes GH acutely induced threonine phosphorylation of both EGFR and ErbB-2, as detected by a monoclonal antibody (PTP101) that recognizes phosphorylation of the consensus sites in the substrates for proline-directed kinases such as ERKs (Huang et al., 2003) . We similarly examined the effects of PRL on the phosphorylation status of EGFR and ErbB-2 in T47D cells (Figure 2 ). Serum-starved cells were exposed to vehicle, PRL or EGF for 15 min before detergent extraction and immunoprecipitation with anti-EGFR (Figure 2a ) or anti-ErbB-2 (Figure 2b) antibodies. Eluates were resolved by SDS-PAGE and immunoblotted sequentially with PTP101 (upper panels), anti-pTyr (middle panels) and anti-EGFR or anti-ErbB-2 (lower panels) ( Figure  2a and b, respectively). As we previously detected for GH stimulation in 3T3-F442A cells (Kim et al., 1999; Huang et al., 2003) , PRL acutely promoted PTP101-reactive phosphorylation of both EGFR and ErbB-2 (upper panels of Figure 2a and b, respectively, lane 2 vs 1) in T47D cells. In these cells, both molecules were basally tyrosine phosphorylated, as evidenced by their detection with anti-pTyr antibody (middle panels of Figure 2a and b, lane 1), suggesting a level of activation of each independent of added EGF. Notably, PRL treatment did not increase basal tyrosine phosphorylation of EGFR in T47D cells (Figure 2a , middle panel, lane 2 vs 1), unlike previous findings for GH in other cell systems (Yamauchi et al., 1997; Huang et al., 2003) . ErbB-2 tyrosine phosphorylation was decreased by PRL treatment (Figure 2b , middle panel, lane 2 vs 1), consistent with our previous findings for GH's effects on ErbB-2 in preadipocytes (Kim et al., 1999) . These PRL-induced changes in threonine and tyrosine phosphorylation were not associated with changes in abundance of either EGFR or ErbB-2 over the period of PRL exposure (lower panels of Figure 2a We further tested the effect of ERK inhibition on PRL-induced EGFR and ErbB-2 PTP101-reactive phosphorylation in the experiments shown in Figure 3 . To address this, we employed PD98059, a specific (Alessi et al., 1995; Dudley et al., 1995) . Pretreatment with PD98059 prevented PRL-induced ERK activation ( Figure 3a , lower panels), as expected. Similarly, PRLinduced PTP101-reactive phosphorylation of EGFR and ErbB-2 was abrogated in the presence of PD98059 (Figures 3a and b, respectively) . In other experiments (not shown), PRL-induced ERK activation and PTP101-reactive EGFR phosphorylation were not prevented by the PKC inhibitor, GF109203X (Toullec et al., 1991) . These data strongly suggest that, like GH-induced phosphorylation of EGFR and ErbB-2 in preadipocytes, PRL-induced PTP101-reactive phosphorylation of these molecules in T47D cells is ERK pathway-(not PKC pathway-) dependent.
Synergistic signaling elicited by collaboration between PRL and EGF We previously found that GH and EGF synergized in an ERK-dependent manner concerning aspects of signaling in preadipocytes (Huang et al., 2003) . Our findings in T47D breast carcinoma cells in Figures 1-3 encouraged us to examine PRL-EGF crosstalk in these cells. We first assessed ERK activity ( Figure 4 ). As PRL and EGF each cause ERK activation, we chose two time points, 15 min (the peak time for PRL-induced ERK activity, as shown in Figure 1b ) and 120 min (when activation by each stimulus alone is minimal), for examination.
As expected, at 15 min PRL caused ERK activity ( Figure 4a , upper panel, lane 2 vs 1), whereas EGF's effect was more robust (lane 3 vs 2). The ERK activity induced by either stimulus alone markedly declined after 120 min (lanes 5, 6 vs 2, 3). Notably, however, the level of ERK activity achieved by costimulation with PRL and EGF was much greater than that achieved by stimulation with either alone at 120 min (lane 7 vs lanes 5, 6).
To determine if such augmentation reflected simply the summation of PRL-induced plus EGF-induced ERK activation or rather reflected synergistic activation (greater than the summation) by cotreatment with PRL and EGF, we performed densitomeric analysis of the data from four such experiments. The results are displayed in Figure 4b . The open bars indicate the sum of the ERK activity elicited by EGF alone plus PRL alone at 15 or 120 min (corresponding to lanes 2 plus 3 and 5 plus 6, respectively, in Figure 4a ); these bars (representing the summation of signals) are thus referred to as 'PRL þ EGF' and their heights were set as 100% for each time point. The closed bars (referred to as 'PRL/EGF') represent the actual ERK activity signal achieved by costimulation with EGF and PRL for each time point (corresponding to lanes 4 and 7 in Figure 4a ) and were plotted relative to the 'PRL þ EGF' signals at each point. At 15 min, the results indicated a B28% increase in actual ERK activation by costimulation compared to that expected from the summation of the two individual stimuli. This difference approached, but did not achieve, statistical significance (P ¼ 0.07). At 120 min, costimulation increased ERK activity by 75% shown in (a), were subjected to densitometric analysis. Comparison of the level of ERK activation induced by PRL and EGF costimulation (referred to as P/E) with the sum of that induced by PRL alone plus that by EGF alone (referred to as P þ E) is displayed, in which P þ E was considered as 100% at each time point. ). Densitomeric analysis (as described above for Figure 4b ) of the pooled data from seven such experiments revealed that cotreatment synergistically activated SHC by roughly 38% (Po0.01) at 15 min and 115% (Po0.01) at 120 min (Figure 5b , PRL/EGF vs PRL þ EGF). Thus, as for ERK activation, PRL cotreatment markedly synergized with EGF to induce SHC activation, again particularly at a later time point.
We also examined downstream consequences of activation of the SHC and ERK pathways by EGF and PRL in T47D cells by monitoring transactivation of a reporter gene driven by two tandem copies of a c-fos enhancer fragment (the p2FTL plasmid (Chen et al., 1987) ) ( Figure 6 ). This reporter was previously shown to be responsive to EGF and GH treatment in other cell types (Chen et al., 1987; Frank et al., 1995; Kim et al., 1998 Kim et al., , 2002 . T47D cells were transfected with p2FTL and serum-starved before treatment with vehicle, PRL (500 ng/ml), EGF (1 nM) or cotreatment with PRL and EGF for 16 h. Cell lysates were assayed for luciferase activity. In a representative experiment (Figure 6a ), PRL alone and EGF alone induced 3.6-and 6.8-fold increase in luciferase activity over basal (vehicle-induced), respectively. However, the combination of PRL and EGF resulted in a 15-fold increase. Pooled data from three such experiments were analysed, as shown in Figure 6b . In this display, the sum of the c-fos transactivation induced by PRL alone and that by EGF alone (PRL þ EGF) within each experiment was considered as 100%. PRL and EGF cotreatment (PRL/ EGF) augmented the c-fos transactivation by 36.078.8% (Po0.05) over the sum of the individual treatments. Thus, the signaling synergy observed for the SHC and ERK pathways was also seen in downstream gene activation.
The Comparison of the level of SHC activation induced by PRL and EGF costimulation (referred to as P/E) with the sum of that induced by PRL alone plus that by EGF alone (referred to as P þ E) is displayed, in which P þ E was considered as 100% at each time point. Modulation of EGF signaling by prolactin Y Huang et al continued activation of these pathways (e.g., after 120 min of exposure). We also examined the effects of PRL and EGF on JAK2 and STAT5 activation ( Figure  7a and b, respectively). JAK2 tyrosine phosphorylation was detected by anti-JAK2 precipitation followed by anti-pTyr immunoblotting; STAT5 tyrosine phosphorylation was detected by immunoblotting of cell extracts with anti-pSTAT5. As expected, PRL activated both JAK2 and STAT5 tyrosine phosphorylation, most robustly after 15 min, but persisting after 120 min (upper panels, lanes 2 and 5 vs 1). In contrast, EGF treatment did not cause activation of either JAK2 or STAT5 in these cells (upper panels, lanes 3 and 6 vs 1). Furthermore, neither PRL-induced JAK2 nor STAT5 tyrosine phosphorylation was affected by the addition of EGF to PRL treatment (upper panels, lanes 4 vs 2 and 7 vs 5). Thus, unlike the augmentation of EGF signaling by cotreatment with PRL, PRL signaling was not augmented by cotreatment with EGF. 
PRL alters EGF-induced EGFR downregulation in an ERK-dependent manner
EGF binding initiates the process of EGFR internalization and degradation, which results in temporary downregulation of EGFR (Wiley, 2003; Wiley et al., 2003) . We previously reported that in preadipocytes GH lessens EGF-induced EGFR degradation (Huang et al., 2003) . Further, GH-mediated attenuation of EGFinduced downregulation was ERK pathway-dependent, correlating with GH-induced threonine phosphorylation of EGFR and GH/EGF signaling synergy. (Huang et al., 2003) . In light of our findings above in T47D cells that PRL caused ERK-dependent EGFR threonine phosphorylation and that PRL augmented aspects of EGF signaling, we investigated the effects of PRL on EGF-induced EGFR downregulation in this cell system (Figure 8 ). Serum-starved cells were exposed to vehicle, PRL, EGF or cotreatment with PRL and EGF acutely (15 min) or for a longer period (120 min), the same conditions used for the assessment of signaling in Figures 4, 5, and 7. Cells were solubilized in a lysis buffer containing 1% SDS and these total cell extracts were resolved by SDS-PAGE and immunoblotted with anti-EGFR to estimate EGFR abundance (Figure 8a ). PRL itself did not affect EGFR mass (lanes 2 and 3 vs 1). As expected, EGF stimulation caused substantial loss of EGFR, evident even after 15-min treatment (lane 4 vs 1), but quite extensive after 120 min (lane 5 vs 1). Notably, however, cotreatment with PRL and EGF resulted in attenuation of the loss of EGFR in comparison with treatment with EGF alone, a difference detectable at 15 min (Figure 8a , upper panel, lane 6 vs 4). Such attenuation was also seen after 120-min treatment (best seen in the longer exposure (lower panel) of Figure 8a , lane 7 vs 5). EGFR abundance was then estimated quantitatively by densitomeric analysis of the results of six such experiments (Figure 8b ). In this display, the EGFR abundance of control (cells treated with vehicle) is considered as 100% and the abundance of EGFR remaining after the indicated treatments is plotted relative to the control. It is evident that cotreatment with PRL significantly reduced EGFinduced EGFR loss at both 15 and 120 min.
We also tested whether the PRL's attenuation of the EGF-induced EGFR downregulation was dependent on the ERK pathway (Figure 8c ). To address this, T47D cells were pretreated with vehicle (lanes 1-3) or PD98059 (lanes 4-6), before stimulation with EGF for 120 min in the absence (lanes 2 and 5) or presence (lanes 3 and 6) of PRL. As expected, EGF treatment for this duration caused substantial loss of EGFR either in the absence or presence of PD98059 (lanes 2 vs 1 and 5 vs 4, respectively). Notably, however, whereas PRL lessened EGF-induced EGFR loss in the absence of PD98059 (lane 3 vs 2), treatment with the ERK inhibitor blocked this protective effect of PRL (lane 6 vs 5). These data indicate that the blunting of EGF-induced EGFR downregulation by PRL is ERK-dependent.
As EGF itself causes PTP101-reactive phosphorylation of EGFR (Figure 2a) , we tested the effect of the ERK pathway inhibitors on EGF-induced EGFR downregulation (Figure 8d and e). For these experiments, we used both PD98059 and another ERK pathway inhibitor, U0126 (Favata et al., 1998) . In the representative experiment shown in Figure 8d , T47D cells were pretreated with vehicle (lanes 1 and 2) or U0126 (lanes 3 and 4) before stimulation with EGF for 15 min. Consistent with the results shown in Figure 8a , stimulation with EGF in the absence of U0126 resulted in a substantial loss of EGFR (upper panel, lane 2 vs 1). As expected, U0126 markedly inhibited EGF-induced ERK activity (middle panel, lane 4 vs 2). Notably, pretreatment with UO126 significantly enhanced EGFinduced EGFR loss (upper panel, lane 4 vs 2) without apparently affecting basal EGFR abundance (upper panel, lane 3 vs 1). Similar results were obtained when PD98059 was used (data not shown). Pooled data from three independent experiments were densitometrically evaluated ( Figure 8e ). In this display, the EGFR abundance of control (without EGF treatment either in the absence or presence of the MEK1 inhibitor) is considered as 100% and the abundance of EGFR remaining after EGF treatment for 15 min is plotted relative to control. Pretreatment with the MEK1 inhibitor significantly enhanced EGF-induced EGFR loss (compare the heights of the two open bars (5572 vs 3273%, Po0.01)). Taken together, these results suggest that ERK-mediated EGFR threonine phosphorylation, whether accomplished by PRL before EGF stimulation or as a result of EGF-induced ERK activation, can modulate EGF-induced EGFR downregulation.
Discussion
Accumulating evidence points to the complexity of cellular signaling networks. It is increasingly appreciated that interactions and crosstalk among signaling pathways allow both integration and diversity in responses to cellular stimuli. EGFR and cytokine receptor family member signaling pathways can interrelate in various ways (Johnson et al., 1996; Fenton and Sheffield, 1997; Wiepz et al., 1997; Yamauchi et al., 1997 Yamauchi et al., , 1998 Yamauchi et al., , 2000 Qiu et al., 1998; Quijano and Sheffield, 1998; Kim et al., 1999; Maus et al., 1999; Badache and Hynes, 2001; Huang et al., 2003; Eisenberg et al., 2004) . We previously focused on interactions between GH/GHR signaling and signaling mediated by intrinsic tyrosine kinase growth factor receptors, including EGFR and ErbB-2, in murine preadipocytes (Kim et al., 1999; Huang et al., 2003 Huang et al., , 2004a . In those cells, GH acutely promoted threonine phosphorylation of both EGFR and ErbB-2, which was detected by an antibody (PTP101) that specifically recognizes consensus phosphorylation sites in the substrates for proline-directed kinases such as ERKs (Kim et al., 1999; Huang et al., 2003) . Such GH-induced phosphorylation was dependent on activation of the ERK pathway and correlated with alteration in EGFR and ErbB-2 signaling and/or trafficking.
In the current study, we examined crosstalk between PRL and EGF signaling systems in T47D human breast cancer cells. We detected PRL-induced PTP101-reactive phosphorylation of both EGFR and ErbB-2, much as we observed in GH-treated preadipocytes. By employing pharmacological inhibitors to block specific signaling pathways, we determined that this PRL-induced phosphorylation was dependent on the ERK pathway, but not the PKC pathway. Importantly, we demonstrated that PRL synergized with EGF to signal via the SHC/ ERK/c-fos cascade, but that JAK2/STAT5 signaling stimulated by PRL was not affected by costimulation with EGF. Finally, we observed that the addition of PRL to EGF treatment significantly retarded EGF-induced EGFR dowregulation in an ERK activation-dependent manner and with a time course that correlated with the synergistic effects of PRL on EGF signaling. These findings suggest that the altered dynamics of EGFR downregulation relates to its ERKdependent phosphorylation and may have important consequences for the combined actions of the two stimuli.
A substantial literature suggests a role for PRL, possibly produced locally, in human cancers, including breast cancer (Goffin et al., 1999; Vonderhaar, 1999; Ben-Jonathan et al., 2002; Clevenger et al., 2003) . Although clinical trials with dopamine agonists to reduce circulating PRL in women with breast cancer have not succeeded (Bonneterre et al., 1988; Anderson et al., 1993; McMurray et al., 1995) , some epidemiologic data suggest correlation between increased serum PRL levels and breast cancer risk in postmenopausal women (Hankinson et al., 1999) . Notably, PRL and PRLR are expressed in nearly all breast cancer samples and some investigators find higher PRLR levels in cancerous tissue vs normal surrounding tissue (Ginsburg and Vonderhaar, 1995; Reynolds et al., 1997; Touraine et al., 1998) . In mice, transgenic overexpression of PRL results in mammary tumor formation (Wennbo et al., 1997) and T47D breast cancer cells xenografted into nude mice respond in vivo to PRL with increased tumor growth (Chen et al., 2002) . The mechanisms of PRL's influence on breast cancer behavior are incompletely understood and could be several (Schroeder et al., 2002; Clevenger et al., 2003; Gutzman et al., 2004 Gutzman et al., , 2005 ; however, given the importance of EGFR and PRL on this form of cancer, we are intrigued by the implications of our data on PRL's ability to augment EGF signaling in T47D cells. Importantly, for our current work with T47D cells, previous studies with this cell line have established that PRL and EGF can cooperate with regard to cell migration and gene activation (Haraguchi et al., 1997; Maus et al., 1999) . Our data suggest that PRL-induced ERK activation could be relevant in the facilitation of signaling collaboration between PRL and EGF.
Our findings of PRL-mediated modulation of EGFR phosphorylation and signaling in T47D cancer cells differ in several respects from previous studies in which normal murine mammary epithelial cells (NMuMG) were used as a model system Sheffield, 1993, 1997; Johnson et al., 1996; Quijano and Sheffield, 1998) . In those studies, PRL treatment of NMuMG cells caused EGFR threonine phosphorylation, detected by anti-phosphothreonine blotting and phosphoamino-acid analysis of 32 P-labeled cells, and this PRL-induced phosphorylation was inhibited by the specific PKC inhibitor, GF109203X (Fenton and Sheffield, 1997; Quijano and Sheffield, 1998) . In contrast, the PRLinduced PTP101-reactive phosphorylation of EGFR we observed in T47D cells was ERK activation dependent and not inhibited by GF109203X. Second, in NMuMG cells, PRL activated PKC, but activated ERK only to a modest degree, and PRL dramatically inhibited EGFinduced Ras/ERK signaling (Johnson et al., 1996; Fenton and Sheffield, 1997) . In contrast, we found that PRL promoted robust ERK and SHC activation in T47D cells, consistent with others' findings in these cells (Acosta et al., 2003) , and that cotreatment with PRL and EGF augmented the SHC/ERK signaling. Finally, PRL decreased both basal and EGF-induced EGFR kinase activity in NMuMG cells (Quijano and Sheffield, 1998) . In contrast, we did not discern reliable changes in either the basal (Figure 2a ) or EGF-induced (not shown) tyrosine phosphorylation of EGFR in T47D cells in response to PRL. These results suggest that the quite different effects of PRL on EGFR function in NMuMG (inhibitory) and T47D (synergistic) cells are both threonine phosphorylation-dependent, but mediated by different kinases and/or phosphorylation sites.
Two major threonine phosphorylation sites are known in the EGFR juxtamembrane cytoplasmic domain, Thr654 and Thr669 (Hunter et al., 1984; Davis and Czech, 1985; Heisermann and Gill, 1988; Takishima et al., 1988) . PKC may directly mediate the Thr654 phosphorylation, whereas Thr669 is thought to be phosphorylated by ERKs (Northwood et al., 1991; Takishima et al., 1991) . We note that Thr669 lies in the only ERK phosphorylation consensus in EGFR and that the EGFR threonine phosphorylation induced by GH (Huang et al., 2003) or PRL (in this study) was not inhibited by a PKC inhibitor. Indeed, our preliminary data indicate that an EGFR with Thr669 mutated to Ala cannot undergo PTP101-detectable phosphorylation in response to GH in a reconstitution system in CHO cells that express GHR (Li et al., 2005) , suggesting that Thr669 is the phosphorylation site for active ERKs elicited by GH. Whether PRL also uses the Thr669 site as GH does for ERK-dependent EGFR threonine phosphorylation is not yet known, but will be an important issue for further investigation.
These distinctions between NMuMG and T47D cells could reflect differences in signaling pathways primarily utilized by PRL and/or in EGFR signaling properties between normal mammary epithelial cells and breast cancer cells. Interestingly, a previous study on crosstalk between EGF and platelet-derived growth factor (PDGF) signaling systems revealed that in Rat-1 fibroblast cells, PDGF antagonized EGF-induced activation of c-Jun N-terminal kinase (JNK) via PDGFmediated protein kinase D (PKD) activation. By contrast, in SF126 glioblastoma cells, PDGF and EGF synergistically activated JNK and neither PDGF nor EGF stimulated PKD activity (Bagowski et al., 1999) . To understand whether the dichotomy in PRL effects on EGFR signaling in NMuMG vs T47D cells reflects fundamental distinctions between normal and neoplastic mammary epithelial cells will require a more comprehensive survey of normal and breast cancer cell lines.
T47D cells express both EGFR and ErbB-2 and both become PTP101 detectibly phosphorylated in response to PRL, in the same manner as what we previously found for both molecules in response to GH in murine preadipocytes (Kim et al., 1999; Huang et al., 2003 Huang et al., , 2004a . In both systems, the GH/PRL-induced threonine phosphorylation of ErbB-2 was accompanied by decreased tyrosine phosphorylation, likely a reflection of diminished kinase activity. As is well appreciated in other systems, EGF does not cause downregulation of ErbB-2 in either cell type (Huang et al., 2003) and GH/ PRL, unlike their effects on EGFR, could not exert influence on this aspect of ErbB-2 behavior. Despite this negative influence on constitutive and EGF-induced ErbB-2 activity, GH and PRL in preadipocytes and T47D cells, respectively, cause a net increase in EGFinduced signaling to the SHC/ERK/c-fos pathway. Notably, although GH alone causes JAK2-dependent tyrosine phosphorylation of EGFR in several systems (Yamauchi et al., 1997; Kim et al., 1999; Huang et al., 2003) , PRL treatment of T47D cells did not itself cause enhanced EGFR tyrosine phosphorylation. Thus, such enhanced EGFR tyrosine phosphorylation is unlikely to explain the shared property of GH and PRL to augment EGF-induced signaling. Rather, we are most impressed with the abilities of GH and PRL to cause in both systems substantial blunting of EGF-induced EGFR downregulation and that this effect is completely prevented by blockade of ERK signaling (Huang et al., 2003) .
After cell surface EGF binding, activated EGFR follows a well-characterized itinerary leading ultimately to downregulation via lysosomal degradation (Wiley, 2003) . EGF-bound EGFR undergoes clathrin-coated pit-mediated endocytosis at a much enhanced rate compared to the constitutive (ligand-independent) rate. After ligand-induced endocytosis, EGFR enters the endosomal pathway. If not recycled to the cell surface (as in the absence of EGF stimulation), EGFR progresses from early to late endosomes and ultimately via the multivesicular bodies to lysosomes. We do not yet know the exact locus in the EGFR downregulatory pathway at which the effects of GH or PRL are exerted, but we favor the hypothesis that these effects require EGFR phosphorylation, likely at Thr-669. In principle, GH-or PRL-induced ERK-mediated threonine phosphorylation of EGFR might affect any of these steps in such a way as to lessen subsequent EGF-induced EGFR downregulation. For example, the rate of EGF-induced EGFR progress through the endocytic pathway could be diminished or the typically low rate of EGFR recycling could be enhanced by GH/PRL treatment. (The latter has been observed, for instance, in response to phorbol 12-myristate 13-acetate (PMA) treatment and was attributed to PKC-dependent Thr-654 phosphorylation (Bao et al., 2000) .) Indeed, GH or PRL cotreatment could modulate EGF-induced EGFR downregulation by virtue of the same ERK-mediated EGFR phosphorylation also brought about by EGF stimulation itself. In this sense, such ERK-mediated threonine phosphorylation could serve as a 'brake' on EGF-induced EGFR downregulation. One might envision, however, differences in the ultimate degree and timing of modulation of receptor downregulation depending on whether the EGFR threonine phosphorylation resulted from heterologous ERK activation (as with GH or PRL cotreatment or pretreatment) before EGF engagement vs subsequent to EGF-induced EGFR kinase activation (as with EGF treatment alone). Deciphering these mechanisms will require more detailed mutagenesis and cell biological studies.
We note that emerging evidence suggests that EGFR signaling may in part emanate from not only the cell surface receptors but also those in the process of postendocytic trafficking (Ceresa and Schmid, 2000; Burke et al., 2001; Di Fiore and De Camilli, 2001; Wiley, 2003) . Thus, our data also suggest the novel hypothesis that effects of PRL (and possibly other ERK-activating cytokines) on breast cancer cells could in part be related to modulation of EGF signaling by alteration of EGFR trafficking. As both PRL and EGF are potentially manipulatable targets in breast cancer (Nicholson et al., 2001; Chen et al., 2002; Clevenger et al., 2003; Lichtner, 2003; Harari, 2004; Laskin and Sandler, 2004; Goffin et al., 2005) , this hypothesis is worthy of further testing in both cellular reconstitution systems and in vivo models.
Materials and methods
Materials
Recombinant human PRL (lot. no. AFP795) was obtained through the National Hormone and Pituitary Program, NIDDK and Dr Albert F Parlow (Harbor-UCLA Medical Center, Torrence, CA, USA). Recombinant human EGF was purchased from Upstate Biotechnology (Lake Placid, NY, USA). The MEK1 inhibitors, PD98059 and U0126, were purchased from Invitrogen (San Diego, CA, USA) and Promega (Madison, WI, USA), respectively.
Antibodies
Polyclonal anti-EGFR and anti-ErbB-2, and monoclonal anti-STAT5 (G-2) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Monoclonal anti-phospho-threonine-proline antibody PTP101 was obtained from Cell Signaling Technology (Beverly, MA, USA). Monoclonal anti-phosphotyrosine antibody 4G10, polyclonal anti-mitogen-activated protein kinase (MAPK) antibody (anti-ERK, recognizing both ERK1 and ERK2) and polyclonal anti-phospho-SHC (pSHC, recognizing phosphorylated SHC protein at Tyr-239) were from Upstate Biotechnology (Lake Placid, NY, USA). Anti-active MAPK antibody (anti-pERK, recognizing the dually phosphorylated Thr-183 and Tyr-185 residues corresponding to the active forms of ERK1 and ERK2) was purchased from Promega Corp. (Madison, WI, USA). Polyclonal anti-phospho-STAT5 antibody (antipSTAT5) was obtained from Zymed Laboratories (San Francisco, CA, USA). Polyclonal anti-SHC antibody was purchased from BD Transduction Laboratories, San Jose, CA, USA. The rabbit polyclonal anti-JAK2 AL33 antiserum (directed at residues 746-1129 of murine JAK2) has been described previously .
Cell culture, starvation, inhibitor pretreatment, growth factor stimulation and protein extraction The human breast cancer cell line, T47D, was from ACTT and cultured in RPMI 1640 medium (Cellgro Inc., Herndon, VA, USA), supplemented with 10% fetal bovine serum, 50 mg/ml gentamicin sulfate, 100 U/ml penicillin and 100 mg/ml streptomycin (all from Biofluids, Rockville, MD, USA). Serum starvation was accomplished by substitution of 0.5% (w/v) bovine serum albumin (BSA) (fraction V, Roche Molecular Biochemicals, Indianapolis, IN, USA) for fetal bovine serum in the culture medium for 16-20 h before experiments. Pretreatments and stimulations were performed at 371C in binding buffer consisting of 25 mM Tris-HCl (pH 7.4), 120 mM NaCl, 5 mM KCl, 1.2 mM MgCl 2 , 0.1% (w/v) BSA and 1 mM dextrose. Serum-starved cells were pretreated with U0126 (10 mM), PD98059 (100 mM), GF109203X (1 mM) or vehicle (as a control) for 60 min before stimulation with PRL (500 ng/ml), EGF (1 nM), PMA (1 mg/ml) or vehicle, as specified in each experiment. Stimulations were terminated by washing the cells with ice-cold phosphate-buffered saline (PBS) supplemented with 0.4 mM sodium orthovanadate (PBS-vanadate). The cells were then harvested by scraping in PBS-vanadate followed by a brief centrifugation at 41C. The cell pellets were solubilized for 15 min at 41C in lysis buffer (150 mM NaCl, 10% (v/v) glycerol, 50 mM Tris-HCl (pH 8.0), 100 mM sodium fluoride, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 10 mM bezamidine, 5 mg/ml aprotinin and 5 mg/ml leupeptin) containing 1% (v/v) Triton X-100. After centrifugation at 15 000 g for 15 min at 41C, the detergent extracts (supernatant) were subjected to immunoprecipitation or were directly electrophoresed and immunoblotted, as indicated below. For examining the abundance of EGFR, the cell pellets were extracted in the above lysis buffer containing 1% (w/v) SDS.
Immunoprecipitation and immunoblotting
For immunoprecipitation, cell extracts (500-1000 mg) were mixed with 5 ml anti-EGFR or anti-ErbB-2 antibody (1 mg) and incubated at 41C for 2 h with continuous agitation. Protein A-Sepharose (20 ml) (Amersham Biosciences, Piscataway, NJ, USA) was added and incubated at 41C for an additional hour. The beads were washed four times with lysis buffer. Laemmli sample buffer eluates were resolved by SDS-PAGE. Proteins resolved by SDS-PAGE were transferred to Hybond ECL nitrocellulose membranes (Amersham Biosciences). The membranes were blocked in Tris-buffered saline with 0.1% Tween (TBST) buffer (20 mM Tris-HCl (pH 7.6), 150 mM NaCl and 0.1% (v/v) Tween 20) containing 2% (w/v) BSA and incubated with primary antibodies (0.5-1 mg/ml according to the manufacturer's suggestions) in TBST buffer. After three washes with TBST, the membranes were incubated with appropriate secondary antibodies (1:10 000 dilution) (Piece Chemical Co., Rockford, IL, USA) and washed three times. The bound antibodies were detected with SuperSignal chemiluminescent substrate (Piece Chemical Co.). Membrane stripping was performed according to the manufacturer's suggestions (Amersham Biosciences).
c-fos-Luciferase transactivation assay T47D cells (70% confluent in a 100 Â 20 mm dish) were transfected with the plasmid p2FTL containing a luciferase reporter gene driven by two tandem copies of a c-fos enhancer fragment (Chen et al., 1987) using LipofectAMINE Plus reagents (Invitrogen, San Diego, CA, USA). The cells were split into one 12-well plate 18-20 h after transfection and grown overnight in culture medium containing 10% fetal bovine serum. The cells were starved for 8 h and then stimulated with vehicle, PRL or EGF, or costimulated with PRL and EGF in triplicate for 16 h. Cells were lysed with luciferase lysis buffer (200 ml/well), and 100 ml of cell lysates were used for luciferase activity assay as described previously (Frank et al., 1995; Kim et al., 2002) .
Densitomeric and statistical analysis
Immunoblots were scanned using a high-resolution scanner (Hewlett-Packard Co., Palo Alto, CA, USA). Densitomeric quantification of images was performed using an image analysis program, Image J (developed by WS Rasband, Research Services Branch, National Institute of Mental Health, Bethesda, MD, USA). Pooled data of densitometry or transactivation assays from several experiments are displayed as mean7s.e. The significance (P-value) of differences of pooled results were estimated using unpaired t-tests.
